Bengaluru, July 16, 2025: Emcure Pharmaceuticals Ltd. (“Emcure”) and Sanofi India Limited (“SIL”) today entered into an exclusive distribution and promotion agreement for SIL’s oral anti-diabetic (OAD) products in India, effective immediately.
Emcure will exclusively distribute and promote the Company’s OAD range of products that include well-established brands like Amaryl® and Cetapin®.
While SIL will continue to own and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India.
There will be no people transition from SIL to Emcure in this arrangement.
Eric Mansion
General Manager Pharma Southeast Asia and India & MCO Lead, Sanofi
“Over 100 million[i] Indians are living with type 2 diabetes and its complexities in India. Of these, >60% people[ii] are living with uncontrolled blood sugar levels and have a higher risk of developing complications, over a long period of time. Sanofi’s commitment to improving their lives and helping them manage their diabetes better remains unwavering. With Emcure’s wide and deeply penetrated presence across India, we’re confident of tapping into the full growth potential of our best-in-class & industry-leading OADs Amaryl® and Cetapin®. This partnership will truly benefit both – the patients who need them and the HCPs who trust and prescribe them.”
Satish Mehta
Chief Executive Office and Managing Director, Emcure Pharmaceuticals Ltd.
“At Emcure, we are committed to improving patient access to high-quality therapies. With our strong distribution network in India, Sanofi’s trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country.”
